Validation of an attenuated live vaccine against babesiosis in native cattle in an endemic area.
The objective of this study was to evaluate in native cattle the use of an in vitro derived attenuated live vaccine (Babesia bovis-Babesia bigemina). Three commercial farms located in a tropical region in Chiapas State, Mexico were included. For each ranch, 40 animals were selected as negative to Babesia spp. by using an immunofluorescent antibody test (IFAT) and PCR. Animals were distributed in four groups with 10 animals each: (i) <9 months, (ii) 9-18, (iii) 18-36 and (iv) >36 months old. From each group, two subgroups were formed with five animals each; one subgroup was vaccinated and the other served as control without vaccination. Monitoring and sampling were carried out initially at vaccination (day 0), at day 7 and then every 4 weeks for 12 months. During the study rectal temperature ( degrees C), packed cell volume (Ht %) and percentage of erythrocytes parasitized were registered, furthermore IFAT and PCR were performed. Prevalence rate at the beginning of the study was 83% by IFAT. During the survey, 26 non-vaccinated of the 120 selected animals (43%) showed clinical symptoms of babesiosis, confirmed by stained smears versus only four (6.6%) of the vaccinated ones. All Babesia-affected animals required specific treatment. Vaccinated cattle showed titres of up to 1 : 1840 and 1 : 1027 for B. bovis and B. bigemina, respectively by IFAT. Protection conferred by vaccination was about 93%. We propose that this vaccine should not only be used in cattle coming from babesiosis free zones, but also in native cattle kept in hyperendemic areas.
UAEM-CU, Mexico, Mexico.
J J
JJ
Ojeda
L
L
Orozco
R
R
Flores
C
C
Rojas
J V
JV
Figueroa
J A
JA
Alvarez
D000818:Animals; D001404:Babesiosis / Q000453:epidemiology / Q000517:prevention & control*; D002417:Cattle; D002418:Cattle Diseases / Q000517:prevention & control*; D019353:Endemic Diseases; D008800:Mexico / Q000453:epidemiology; D016052:Protozoan Vaccines / Q000276:immunology*; D014613:Vaccines, Attenuated / Q000276:immunology
D016052:Protozoan Vaccines; D014613:Vaccines, Attenuated